Roche CEO Schwan Says New Medicines Driving 'Strong Growth'

The transcript discusses the strong start to 2019, driven by newly launched medicines, leading to a raised growth outlook. It highlights the promising pipeline, including new cancer and hemophilia treatments, and addresses competition from biosimilars. The M&A strategy focuses on bolt-on acquisitions, exemplified by the Spark acquisition, enhancing gene therapy capabilities. The transcript also covers the impact of Brexit on medicine supply and the US pricing strategy, emphasizing innovation and value for patients.

What was the primary reason for Roche's strong start in 2019?

• Expansion into new markets

• Newly launched medicines

• Increased marketing efforts

• Reduction in operational costs

Which recently launched medicine is mentioned as having a strong uptake in multiple sclerosis?

• Tecentriq

• Him Libre

• Polatuzumab

• Oak leaves

What is the focus of Roche's M&A strategy?

• Bolt-on acquisitions

• Large-scale acquisitions

• Divesting non-core assets

• Merging with competitors

What area does Roche aim to expand with the Spark acquisition?

• Diagnostics

• Cancer treatments

• Gene therapies

• Neuroscience

How does Roche plan to handle the potential impact of Brexit?

• By reducing their UK workforce

• By relocating operations to the EU

• By ensuring a steady supply of medicines

• By increasing prices in the UK

What is Roche's approach to pricing new medicines in the US?

• Pricing based on production costs

• Pricing above older medicines

• Pricing below or at the cost of older medicines

• Pricing based on competitor prices

What is Roche's strategy to maintain its position in the US market?

• Focus on innovation and true value

• Focus on cost-cutting measures

• Focus on expanding sales force

• Focus on aggressive marketing